Specifically, SGLT2 inhibitors were associated with a reduced risk for incident anemia events (HR, 0.79; 95% CI, 0.71-0.87) but not for initiation of anemia treatment (HR, 0.99; 95% CI, 0.83-1.19) (Figure 2). This evidence concerns the gene SLC5A2 and anemia.